2024-01-24 10:22:27 ET
Summary
- Agenus Inc. has unveiled promising data from the NEST-1 study, showing the potential of the combination of botensilimab and balstilimab in colorectal cancer treatment.
- The combination demonstrated significant tumor regression and the elimination of ctDNA, opening new possibilities for improving patient outcomes.
- Agenus has a robust pipeline and platform technology, positioning the company for substantial growth in the future.
Agenus Inc. ( AGEN ), a pioneer in immunological cancer treatments, has recently unveiled impressive results from the NEST-1 study. This investigator-sponsored trial ("IST") focused on evaluating the combination of botensilimab and balstilimab ((BOT/BAL)) in the neoadjuvant setting for colorectal cancer ((CRC)). The data from the NEST-1 study present BOT/BAL as a potential game-changer in CRC treatment. The combination's ability to induce significant tumor regression and eliminate ctDNA opens new possibilities for improving patient outcomes and reducing reliance on traditional treatments. Once again, Agenus has produced impressive clinical data that shows that they continue to advance immunological agents for cancer therapy. Yet, AGEN continues to trade around $0.52-$0.75 per share with abysmal technical grades. Indeed, I see AGEN to be a very speculative ticker at this time, however, I believe the market has taken the selling pressure too far for the company’s long-term prospects. As a result, I am looking to advantage of this risk-reward opportunity and add to my dormant AGEN in the immediate term....
Read the full article on Seeking Alpha
For further details see:
Agenus: Taking Advantage Of The Risk-Reward Opportunity